2014 Cancer Diagnostics Market Opportunities: US, UK, Spain, France, Germany, Italy and Japan Analyzed in New Research Reports at ReportsnReports.com

2014 Cancer Diagnostics Market Opportunities for US, UK, Spain, France, Germany, Italy and Japan analyzes potential applications of various diagnostic technologies and forecasts sales of major tumor markers and market segment.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, Texas (PRWEB) September 13, 2013

These research reports on Cancer Diagnostics Market for US, UK, Spain, France, Germany, Italy and Japan are new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. These reports examine trends in the US, UK, Spain, France, Germany, Italy and Japan cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Browse Reports Individually on Cancer Diagnostics Market for US, UK, Spain, France, Germany, Italy and Japan :

Business Opportunities and Strategic Recommendations for Cancer Diagnostics Market for US, UK, Spain, France, Germany, Italy and Japan

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests—Over 200 current and emerging assays including:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

Sales and market shares of major suppliers, by individual cancer diagnostic test.

Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:

Hospitals
Commercial/Private Laboratories
Physician Offices/Group Practices
Cancer Clinics

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Cancer statistics, etiology and recent developments.

Current and Emerging Products

Review of over 200 current and emerging cancer diagnostic tests,
including:

Biochemical Markers
Oncogenes
Growth Factors
Hormones
Colony Stimulating Factors
Lymphokines
Immunohistochemical Stains, and others.

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review
Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Major Company Profile: Abbott, AdnaGen, Agilent Technologies, Applied Gene Technologies, Arca/Nuvelo, Beckman Coulter/Danaher, Becton Dickinson, Biomedical Diagnostics, bioMerieux, Bio-Rad, CellSearch, Cepheid, Correlogic Systems/Vermillion, Decode, Diadexus, Diagnocure, Diasorin Eiken Chemical, Epigenomics, Enterix, Enzo Biochem, Exact Sciences, Fujirebio/Innogenetics, Guided Therapeutics, Hologic/Gen-Probe, Kreatech, Kyowa Medex, Life Technologies, Mackay Life Sciences, Myriad Genetics, Nanogen Elitech, OncoLab, Ortho-Clinical Diagnostics, Panacea Pharmaceuticals, Polartechnics, Polymedco, PreMD, Qiagen/Ipsogen, Quest Diagnostics, Radient Pharmaceuticals, Roche Scienion, Sequenom, Siemens Healthcare, Takara Bio, Targeted Diagnostics & Therapeutics, Tosoh Veridex, Wako Pure Chemicals, Wallac/PE, Zila

About Us

ReportsnReports.com is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe.


Contact

Follow us on: Contact's Google Plus

Past News Releases Group Rss Subscribe